MedTrace Logo

Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients

NCT06332079 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-01-05

No results posted yet for this study

Summary

The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression free rate 9- and 8-months for cohort A and B, respectively.

Conditions

  • Colorectal Cancer Metastatic

Interventions

PROCEDURE

166Holmium TARE

166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.

DRUG

Cetuximab

Target agent

DRUG

Panitumumab

Target agent

DRUG

5-Fluorouracil

Chemotherapy

DRUG

Bevacizumab

Target agent

DRUG

Capecitabine

Chemotherapy

Sponsors & Collaborators

  • Gruppo Oncologico del Nord-Ovest

    lead OTHER

Principal Investigators

  • Gianluca Masi, MD · Azienda Ospedaliero, Universitaria Pisana

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-13
Primary Completion
2025-12-16
Completion
2025-12-16

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06332079 on ClinicalTrials.gov